GlassScriptPhysician profile
Miroslav Backonja
NPI 1306818513
$21,968.57
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $9,673.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $6,070.90 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $5,947.75 | 2019 | |
| Lilly USA, LLC | $3,900.00 | 2020 | |
| Grt US Holding, INC. | $2,940.00 | 2020 | |
| Sk Life Science, INC. | $2,833.33 | 2020 | |
| Pfizer INC. | $188.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miroslav Backonja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.